VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 126 filers reported holding VERVE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.44 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,443,474 | -84.2% | 1,115,466 | -57.0% | 0.00% | -83.3% |
| Q1 2024 | $34,424,389 | +3.0% | 2,592,198 | +8.1% | 0.02% | -4.0% |
| Q4 2023 | $33,422,600 | +17.4% | 2,397,604 | +11.7% | 0.02% | +8.7% |
| Q3 2023 | $28,472,442 | -30.5% | 2,147,243 | -1.8% | 0.02% | -28.1% |
| Q2 2023 | $40,984,819 | +77.9% | 2,185,857 | +36.8% | 0.03% | +88.2% |
| Q1 2023 | $23,043,073 | -3.1% | 1,597,994 | +30.1% | 0.02% | -10.5% |
| Q4 2022 | $23,770,449 | -10.8% | 1,228,447 | +58.4% | 0.02% | -13.6% |
| Q3 2022 | $26,645,000 | +1413.1% | 775,697 | +573.2% | 0.02% | +2100.0% |
| Q2 2022 | $1,761,000 | -32.7% | 115,232 | +62.4% | 0.00% | -50.0% |
| Q4 2021 | $2,616,000 | -29.0% | 70,950 | -9.5% | 0.00% | 0.0% |
| Q3 2021 | $3,686,000 | – | 78,421 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $9,802,988 | 3.68% |
| Alphabet Inc. | 12,349,086 | $60,263,539 | 3.05% |
| Casdin Capital, LLC | 3,059,094 | $14,928,379 | 1.14% |
| Novo Holdings A/S | 2,400,000 | $11,712,000 | 0.68% |
| MPM BioImpact LLC | 638,163 | $3,114,235 | 0.48% |
| Redmile Group, LLC | 1,463,406 | $7,141,421 | 0.43% |
| Palo Alto Investors LP | 575,817 | $2,809,987 | 0.33% |
| EcoR1 Capital, LLC | 1,250,000 | $6,100,000 | 0.19% |
| Vestal Point Capital, LP | 500,000 | $2,440,000 | 0.18% |
| PDT Partners, LLC | 333,864 | $1,629,256 | 0.15% |